Literature DB >> 15637120

Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation.

Claudia Penna1, Giuseppe Alloatti, Sandra Cappello, Donatella Gattullo, Giovanni Berta, Barbara Mognetti, Gianni Losano, Pasquale Pagliaro.   

Abstract

Ischemic preconditioning (IP) is a cardioprotective mechanism against myocellular death and cardiac dysfunction resulting from reperfusion of the ischemic heart. At present, the precise list of mediators involved in IP and the pathways of their mechanisms of action are not completely known. The aim of the present study was to investigate the role of platelet-activating factor (PAF), a phospholipid mediator that is known to be released by the ischemic-reperfused heart, as a possible endogenous agent involved in IP. Experiments were performed on Langendorff-perfused rat hearts undergoing 30 min of ischemia followed by 2 h of reperfusion. Treatment with a low concentration of PAF (2 x 10(-11) M) before ischemia reduced the extension of infarct size and improved the recovery of left ventricular developed pressure during reperfusion. The cardioprotective effect of PAF was comparable to that observed in hearts in which IP was induced by three brief (3 min) periods of ischemia separated by 5-min reperfusion intervals. The PAF receptor antagonist WEB-2170 (1 x 10(-9) M) abrogated the cardioprotective effect induced by both PAF and IP. The protein kinase C (PKC) inhibitor chelerythrine (5 x 10(-6) M) or the phosphoinositide 3-kinase (PI3K) inhibitor LY-294002 (5 x 10(-5) M) also reduced the cardioprotective effect of PAF. Western blot analysis revealed that following IP treatment or PAF infusion, the phosphorylation of PKC-epsilon and Akt (the downstream target of PI3K) was higher than that in control hearts. The present data indicate that exogenous applications of low quantities of PAF induce a cardioprotective effect through PI3K and PKC activation, similar to that afforded by IP. Moreover, the study suggests that endogenous release of PAF, induced by brief periods of ischemia and reperfusion, may participate to the triggering of the IP of the heart.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15637120     DOI: 10.1152/ajpheart.00599.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  16 in total

1.  Gene expression changes associated with myocarditis and fibrosis in hearts of mice with chronic chagasic cardiomyopathy.

Authors:  Milena Botelho Pereira Soares; Ricardo Santana de Lima; Leonardo Lima Rocha; Juliana Fraga Vasconcelos; Silvia Regina Rogatto; Ricardo Ribeiro dos Santos; Sanda Iacobas; Regina Coeli Goldenberg; Dumitru Andrei Iacobas; Herbert Bernard Tanowitz; Antonio Carlos Campos de Carvalho; David Conover Spray
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

2.  Ouabain triggers preconditioning through activation of the Na+,K+-ATPase signaling cascade in rat hearts.

Authors:  Sandrine V Pierre; Changjun Yang; Zhaokan Yuan; Jennifer Seminerio; Christian Mouas; Keith D Garlid; Pierre Dos-Santos; Zijian Xie
Journal:  Cardiovasc Res       Date:  2006-11-06       Impact factor: 10.787

3.  Fenofibrate attenuates impaired ischemic preconditioning-mediated cardioprotection in the fructose-fed hypertriglyceridemic rat heart.

Authors:  Lalita Babbar; Nanjaian Mahadevan; Pitchai Balakumar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-01-17       Impact factor: 3.000

4.  Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial KATP channels and ROS signalling.

Authors:  Maria-Giulia Perrelli; Francesca Tullio; Carmelina Angotti; Maria Carmela Cerra; Tommaso Angelone; Bruno Tota; Giuseppe Alloatti; Claudia Penna; Pasquale Pagliaro
Journal:  Pflugers Arch       Date:  2013-01-15       Impact factor: 3.657

5.  A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.

Authors:  Peter J Leary; Surender Rajasekaran; R Ray Morrison; Elaine I Tuomanen; Thomas K Chin; Polly A Hofmann
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-04-25       Impact factor: 4.733

6.  pGlu-serpinin protects the normotensive and hypertensive heart from ischemic injury.

Authors:  T Pasqua; B Tota; C Penna; A Corti; M C Cerra; P Loh Y; T Angelone
Journal:  J Endocrinol       Date:  2015-09-23       Impact factor: 4.286

Review 7.  Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future.

Authors:  Michael V Cohen; James M Downey
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

Review 8.  Circulating blood cells and extracellular vesicles in acute cardioprotection.

Authors:  Sean M Davidson; Ioanna Andreadou; Lucio Barile; Yochai Birnbaum; Hector A Cabrera-Fuentes; Michael V Cohen; James M Downey; Henrique Girao; Pasquale Pagliaro; Claudia Penna; John Pernow; Klaus T Preissner; Péter Ferdinandy
Journal:  Cardiovasc Res       Date:  2019-06-01       Impact factor: 10.787

9.  Involvement of the ornithine decarboxylase/polyamine system in precondition-induced cardioprotection through an interaction with PKC in rat hearts.

Authors:  Ya-Jun Zhao; Wei-Hua Zhang; Chang-Qing Xu; Hong-Zhu Li; Li-Na Wang; Hong Li; Yi-Hua Sun; Yan Lin; Li-Ping Han; Li Zhang; Yie Tian; Rui Wang; Bao-Feng Yang; Wei-Min Li
Journal:  Mol Cell Biochem       Date:  2009-06-25       Impact factor: 3.396

10.  Ginkgolide B reduces atherogenesis and vascular inflammation in ApoE(-/-) mice.

Authors:  Xiyun Liu; Gexin Zhao; Yan Yan; Li Bao; Beidong Chen; Ruomei Qi
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.